In a double-blind phase III clinical trial to test the feasibility of inducing oral tolerance to myelin basic protein and PLP, high doses of myelin Ags were administered, and although TGF-β-secreting CD4+ T cells were induced [30], no differences in MS outcomes between placebo and treated were observed [31]. Here, CD4 is linked to myeloid sarcoma.